B cell lymphoma is cancer that starts in B lymphocytes, a type of white blood cell that normally fights infection

B cell lymphoma occurs when B lymphocytes—cells in your immune system that produce antibodies—begin to grow abnormally and multiply without control. Unlike normal B cells, which live for weeks or months and then die, cancerous B cells can live for years and accumulate in your lymph nodes, bone marrow, spleen, and other organs. This uncontrolled growth crowds out healthy cells and disrupts how your immune system works.

B cell lymphomas are not all the same disease. There are dozens of subtypes, each with different growth patterns, responses to treatment, and outcomes. Some grow slowly over years (called indolent lymphomas), while others grow quickly and require urgent treatment (called aggressive lymphomas). Knowing which subtype you have matters because it shapes what treatment your doctor will recommend and what to expect.

Key Takeaways

  • B cell lymphoma starts when B lymphocytes become cancerous and multiply uncontrolled, crowding out healthy immune cells.
  • The disease has many subtypes—some grow slowly and some grow quickly—and the subtype determines which treatments are used.
  • Doctors identify the specific subtype through a biopsy of affected tissue, which is essential before treatment begins.
  • Some B cell lymphomas can go into remission with treatment, while others are managed as chronic conditions over many years.

How B cell lymphoma develops and spreads

B cell lymphoma begins with a single B lymphocyte that acquires genetic changes, usually over years or decades. These changes disable the cell's normal "stop" signals—the mechanisms that tell cells when to die or stop dividing. Once a cell loses these controls, it divides repeatedly, and each new cell carries the same genetic flaw. Over time, millions of identical cancerous cells accumulate.

The cancer spreads through the lymphatic system, the network of vessels and nodes that carries immune cells throughout your body. Cancerous B cells lodge in lymph nodes (which is why swollen nodes are often the first sign), and they can also settle in the bone marrow, spleen, liver, lungs, or other organs. The pattern of spread varies by subtype—some lymphomas stay localized to a few nodes for years, while others spread widely relatively quickly.

Common subtypes and what they mean

Diffuse large B cell lymphoma (DLBCL) is the most common type overall. It grows quickly, but many people respond well to standard chemotherapy combinations. Follicular lymphoma grows slowly and often does not cause symptoms early on, but it is harder to cure completely. Marginal zone lymphomas (including nodal, splenic, and extranodal types) also grow slowly and may not need immediate treatment. Lymphoplasmacytic lymphoma is often associated with a blood protein abnormality called Waldenstrom macroglobulinemia.

There are also Burkitt lymphoma, which grows very aggressively and requires intensive treatment but can be cured in many cases, and primary mediastinal B cell lymphoma, which starts in the chest and is more common in young adults. Your doctor will order specific tests—including flow cytometry, genetic testing, and sometimes imaging—to determine which subtype you have, because the subtype guides every treatment decision.

Symptoms and how the disease is diagnosed

Many people first notice swollen lymph nodes in the neck, armpit, or groin that do not go away after a few weeks. Some experience B symptoms—fever, night sweats, and unintended weight loss—which can signal more aggressive disease. Others have no symptoms at all and discover the lymphoma by accident during imaging or blood work for another reason.

Diagnosis requires a biopsy, a procedure in which a doctor removes a small sample of affected tissue and a pathologist examines it under a microscope. The biopsy shows whether the cells are cancerous, what type they are, and sometimes what genetic changes they carry. Your doctor may also order blood tests, imaging (CT or PET scans), and bone marrow biopsy to see how far the disease has spread. This staging process determines whether treatment should start right away or whether you can safely watch and wait.

Stages and prognosis

B cell lymphomas are staged from I to IV based on how many lymph node regions are involved and whether the cancer has spread to organs outside the lymph system. Stage I means one node region is affected; stage IV means the disease is in the bone marrow, liver, lungs, or other organs. Prognosis—the likely course of the disease—depends on the subtype, the stage at diagnosis, your age, and how well your organs are functioning.

For aggressive lymphomas like DLBCL, prognosis is often better than for slow-growing types because aggressive cancers respond more reliably to chemotherapy. For slow-growing lymphomas, many people live for years or decades with the disease, sometimes without needing treatment. Doctors use scoring systems like the International Prognostic Index to estimate outcomes, but these are population averages—individual outcomes vary widely.

Treatment approaches for B cell lymphoma

Treatment depends on the subtype, stage, and whether you have symptoms. For aggressive lymphomas, the standard first treatment is usually chemotherapy combined with rituximab, a monoclonal antibody that targets a protein on B cell surfaces. This combination, called R-CHOP or similar regimens, works by killing cancer cells through multiple mechanisms at once.

For slow-growing lymphomas, doctors often recommend watch and wait initially—monitoring the disease with regular scans and blood tests but not treating unless symptoms develop or the disease progresses. When treatment becomes necessary, options include rituximab alone, chemotherapy, targeted drugs that block specific pathways cancer cells depend on, or newer immunotherapies. Some people eventually need a stem cell transplant, either autologous (using your own cells) or allogeneic (using donor cells), especially if the disease returns after initial treatment.

Living with B cell lymphoma after treatment

After treatment ends, you will have follow-up visits with your oncologist at regular intervals—initially every few weeks or months, then less frequently as time passes. These visits include physical exams and sometimes imaging or blood tests to watch for recurrence. Many people go into remission, meaning scans and blood work show no evidence of disease, though some lymphomas can return months or years later.

Side effects from treatment can persist after cancer is gone. Chemotherapy can cause fatigue, nerve damage, heart problems, or increased risk of other cancers years later. Rituximab can lower infection-fighting cells temporarily. Your doctor will discuss what to watch for and when to report new symptoms. Support groups, counseling, and rehabilitation programs can help with the physical and emotional recovery after treatment.

Frequently Asked Questions

Is B cell lymphoma the same as leukemia?

No. Both are blood cancers involving white blood cells, but lymphoma is cancer of lymphocytes in lymph nodes and organs, while leukemia is cancer of blood cells in the bone marrow and bloodstream. A person can have both, but they are diagnosed and treated differently.

Can B cell lymphoma run in families?

Most B cell lymphomas are not inherited. They develop from genetic changes that happen during a person's lifetime, not from genes passed down from parents. However, some people may have a slightly higher risk if close relatives had lymphoma, though the link is weak.

What does remission mean, and does it mean I am cured?

Remission means scans and blood tests show no evidence of disease. For aggressive lymphomas, remission often lasts years or indefinitely. For slow-growing types, remission may be temporary and the disease may return. Doctors use "remission" rather than "cured" because some lymphomas can recur after many years.

Will I need chemotherapy even if my lymphoma grows slowly?

Not necessarily. Many slow-growing lymphomas are monitored without treatment for months or years. Treatment starts only if you develop symptoms, the disease spreads significantly, or blood counts drop dangerously. This approach avoids side effects while the disease is not causing harm.

Can newer drugs like CAR-T cell therapy treat B cell lymphoma?

Yes, for certain subtypes and situations. CAR-T cell therapy involves removing your own T cells, genetically engineering them to recognize cancer cells, and infusing them back. It is approved for some B cell lymphomas that have not responded to standard treatment, though it is not yet a first-line option for most patients.